出典:Wikipedia
出典:『Wikipedia』 (2011/07/01 05:28 UTC 版)
Alogliptin (codenamed SYR-322) is an investigational anti-diabetic drug in the DPP-4 inhibitor class, being developed by Takeda Pharmaceutical Company. In January 2008, Takeda submitted a New Drug Application for alogliptin to the U.S. Food and Drug Administration, after positive results from Phase III clinical trials. However, the FDA submission was suspended or withdrawn in June 2009 needing more data.